Idorsia reports positive data for paediatric insomnia study of daridorexant
Idorsia has reported positive top-line data from its Phase II dose-finding trial evaluating daridorexant, a dual orexin receptor antagonist, for …
Post
-
-
Prilenia and Ferrer enrol first participant in PREVAiLS Phase III trial
Prilenia Therapeutics and Ferrer have enrolled the first participant in the pivotal Phase III PREVAiLS clinical trial assessing pridopidine in …
-
J&J’s Spravato touts durable anti-depressant benefits in real-world study
A real-world study has revealed the long-term impact of Johnson & Johnson’s (J&J) Spravato (esketamine) in treatment-resistant depression (TRD), which …
-
Ayahuasca-derived DMT study shows positive effects on depression therapy in trials
Interest in psychedelic medicines has accelerated in recent years, and new research focusing on dimethyltryptamine (DMT), the main psychoactive compound …
-
Viridian Therapeutics’ stock sinks despite positive Phase III TED data
Viridian Therapeutics stock has fallen by 38%, despite its active thyroid eye disease (TED) drug meeting the primary endpoints of …
-
Prilenia and Ferrer enrol first participant in PREVAiLS Phase III trial
Prilenia Therapeutics and Ferrer have enrolled the first participant in the pivotal Phase III PREVAiLS clinical trial assessing pridopidine in …
-
From compliance to culture: Lessons from a quality leader on pharma’s next imperative
We spoke with Grace Breen, Senior Vice President, Quality at Sharp about the role of quality in a CDMO environment, …
-
J&J’s Spravato touts durable anti-depressant benefits in real-world study
A real-world study has revealed the long-term impact of Johnson & Johnson’s (J&J) Spravato (esketamine) in treatment-resistant depression (TRD), which …
-
Ayahuasca-derived DMT study shows positive effects on depression therapy in trials
Interest in psychedelic medicines has accelerated in recent years, and new research focusing on dimethyltryptamine (DMT), the main psychoactive compound …
-
Viridian Therapeutics’ stock sinks despite positive Phase III TED data
Viridian Therapeutics stock has fallen by 38%, despite its active thyroid eye disease (TED) drug meeting the primary endpoints of …
-
2025 dominated in ALS research
Amyotrophic lateral sclerosis (ALS) is a progressive disorder that affects motor neurons responsible for controlling voluntary muscle movement. As these …
-
New Phase II safety data supports enpatoran’s move to Phase III for cutaneous lupus
At SLEuro 2026, Merck KGaA (Merck; known as EMD Serono in the US and Canada) presented new safety and tolerability …
-
J&J reports results from ICONIC 52-week trials of Icotyde
Johnson & Johnson (J&J) has reported new 52-week data from the Phase III ICONIC-ADVANCE 1, ICONIC-ADVANCE 2, and ICONIC-LEAD trials, …
-
Lantern receives FDA clearance for paediatric STAR-001 CNS trial
Starlight Therapeutics' wholly owned subsidiary Lantern Pharma has secured the US Food and Drug Administration (FDA) clearance for its investigational …
-
Consecutive approvals of Opdivo for Hodgkin’s lymphoma to boost sales growth
On 20 March, Bristol Myers Squibb (BMS) announced that the FDA granted approval for Opdivo (nivolumab), an immune checkpoint inhibitor …
